SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
Welcome to the International Immuno-Oncology Biomarker Working Group on Breast Cancer
  • Registration
  • Contact Us
  • LOGIN

International TILS Working Group

  • HOME
    • Membership
    • Funding
    • Who we are
    • Mission
    • Composition of the group
    • Core group
    • Contact Us
    • FAQs
  • RESEARCH & EDUCATION
    • General
      • What are TILs and why are they important ?
      • Presentations
      • Literature Update
      • Q&A on TIL-assessment
      • Researcher Resources
      • Pathology Resources
    • Train yourself !Learn to score TILS
      • … Tutorial Videos
      • … in invasive breast cancer
      • … in solid tumors and in the metastatic setting
      • … in residual disease after treatment
      • … in DCIS
      • … Reference images and pitfalls
    • Ongoing Projects
      • Incorporation of TILs in the Residual Cancer Burden Index
      • Artificial Intelligence / Deep Learning / Machine Learning approaches to TIL-assessment
      • Coming soon: Machine Learning & Clinical Trials
    • Working Groups
      • … on TILs and DCIS
      • … on TILs and Machine Learning Algorithms
      • … on TILs in residual Disease
      • .. on TILs in solid tumors other than Breast Cancer
      • … on TILs in mouse models
  • BLOG
  • NEWS
  • PARTNERS & CAREERS
  • MEETINGS
Teach yourself to score TILs!
  • Home
  • Core Group

Core Group

The core group members are selected by the chair and co-chair based on an established and documented track record in the oncology biomarker area. This list of persons is approved by the Working Group membership.

Members are :

Core GroupAffiliation
Roberto Salgado (co-Chair)Department of Pathology, GZA-ZNA Hospitals, Antwerp; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
Sherene Loi (co-chair)Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Parkville, Australia
Carsten Denkert (co-chair)Institute of Pathology, University Hospital Marburg UKGM , Germany
Sunil BadveDepartment of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA.
Sandra DemariaDepartment of Pathology, Weill-Cornell Medicine, New York, USA
Sylvia AdamsPerlmutter Cancer Center, New York University Medical School, New York, USA
Stefan MichielsService de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay, Villejuif, France
David RimmDepartment of Pathology, Yale University School of Medicine, New Haven, USA
Fraser SymmansDepartment of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA
Stephen HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
John BartlettOntario Institute for Cancer Research, Toronto, Canada; IGGM Edinburgh, UK
Torsten NielsenGenetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
Christos SotiriouDepartment of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Giuseppe VialeDepartment of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
Giancarlo PruneriFondazione Istituto di Ricovero e Cura a Carattere Scientifico–Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Italy
Sibylle Loibldlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany
Lajos PusztaiDepartment of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA

Overview Articles

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Categories

  • New
  • TILs in machine learning algorithms

Topics discussed

Follow me on Twitter

Tweets by @TILsWorkGroup

Blog Archive

  • February 2019
  • January 2018
Website powered by Copyright © 2022 - 2022. All rights reserved.

Website general Terms & Conditions

info@tilsinbreastcancer.org

TOP